Kenvue Inc. (NYSE:KVUE) Shares Sold by Keeler Thomas Management LLC

Keeler Thomas Management LLC lessened its position in Kenvue Inc. (NYSE:KVUE) by 2.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 195,431 shares of the company’s stock after selling 4,871 shares during the period. Keeler Thomas Management LLC’s holdings in Kenvue were worth $4,172,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Grove Bank & Trust lifted its position in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new stake in Kenvue in the 4th quarter valued at about $29,000. Fortitude Family Office LLC increased its stake in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of Kenvue during the 3rd quarter worth about $35,000. Finally, Versant Capital Management Inc boosted its position in shares of Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after acquiring an additional 1,441 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $23.33 on Tuesday. The business’s 50-day simple moving average is $21.33 and its 200 day simple moving average is $22.21. The company has a market cap of $44.72 billion, a P/E ratio of 44.01, a PEG ratio of 2.62 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.52%. Kenvue’s dividend payout ratio is currently 154.72%.

Analysts Set New Price Targets

Several brokerages recently commented on KVUE. Piper Sandler upped their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Citigroup cut their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Barclays cut their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and a consensus target price of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.